Prevention of Cervical Cancer: Challenges and Perspectives of HPV Prophylactic Vaccines

2006 ◽  
pp. 184-205 ◽  
Author(s):  
Joseph Monsonego
Keyword(s):  
Cervical Cancer ◽  
Prophylactic Vaccines

Prophylactic human papillomavirus vaccines: the beginning of the end of cervical cancer

2004 ◽  
Vol 14 (5) ◽  
pp. 751-761 ◽  
Author(s):  
W. A. A. Tjalma ◽  
M. Arbyn ◽  
J. Paavonen ◽  
T. R. Van Waes ◽  
J. J. Bogers
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Neutralizing Antibodies ◽  
Hpv Vaccination ◽  
Phase Iii ◽  
Hpv Vaccines ◽  
Therapeutic Vaccines ◽  
The Status ◽  
Prophylactic Vaccines

Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could become a very rare disease. Two types of HPV vaccines can be distinguished: (i) therapeutic vaccines which induce cellular immunity targeted against epithelial cells infected with HPV and (ii) prophylactic vaccines inducing virus-neutralizing antibodies protecting against new but not against established infections. At present, several vaccines have been developed and tested in clinical trials. The vaccines are generally well tolerated and highly immunogenic. The current clinical data indicate that prophylactic vaccines are very effective against new persistent infections and the development of cervical intraepithelial lesions. The protection is type specific. However, the follow-up of the vaccination trials is still short. The effect of HPV vaccines on future cancer incidence will only be known after decades of follow-up. This article will address the status of recently terminated phase II and currently running phase III trials with prophylactic HPV vaccines.

scholarly journals Development Status and trend of HPV vaccine

2013 ◽  
Vol 2 (1) ◽  
Author(s):  
Shuyang Guo ◽  
Yunpeng Wang
Keyword(s):  
Cervical Cancer ◽  
Human Papilloma Virus ◽  
Hpv Vaccine ◽  
Significant Morbidity ◽  
Cervical Cancer Incidence ◽  
Papilloma Virus ◽  
Development Status ◽  
The Status ◽  
Hpv Types ◽  
Prophylactic Vaccines

<p>Cervical cancer causes significant morbidity and mortality world widely, and human papilloma virus is the major factor that causes cervical cancer incidence. The carcinogenic proteins of HPV can induce malignant metastasis of cervical squamous epithelial cells. There are currently two human papilloma virus prophylactic vaccines listed, but the protection offered by current vaccines is primarily against HPV types used to derive the vaccine. So we review the status and progress of the HPV vaccine in recent years, and the potential clinical application of the vaccine.</p>

scholarly journals Attenuated Salmonella carrying plasmid co-expressing HPV16 L1 and siRNA-E6 for cervical cancer therapy

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Junyu Chen ◽  
Shuhua Zhao ◽  
Wenxi Tan ◽  
Taiwei Wang ◽  
Shan Wu ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Lower Cost ◽  
Hpv Infection ◽  
Effective Prevention ◽  
E7 Gene ◽  
Prophylactic Vaccines ◽  
E6 And E7 ◽  
Prevention Method

AbstractHuman papillomavirus (HPV) infection is the major etiological factor for cervical cancer. HPV prophylactic vaccines based on L1 virus-like particles have been considered as an effective prevention method. However, existing recombination vaccines are too expensive for developing countries. DNA vaccines might be a lower-cost and effective alternative. In this study, a plasmid (pcDNA3.1-HPV16-L1) and a co-expressing plasmid (pcDNA3.1-HPV16-L1-siE6) carried by attenuated Salmonella were constructed and their prevention and treatment effect on cervical cancer were observed, respectively. The results showed that pcDNA3.1-HPV16-L1 carried by attenuated Salmonella could induce the production of HPV16-L1 antibodies, IL-2 and INF-γ in mice serum, which presented its prevention effect on HPV. Subsequently, E6 and E7 gene silencing by pCG-siE6 inhibited the growth of cervical cancer both in vitro and in vivo. Furthermore, L1 up-regulation and E6/E7 down-regulation caused by co-expressing plasmid (pcDNA3.1-HPV16-L1-siE6) contributed to a significant anti-tumor effect on the mice. This study suggests that pcDNA3.1-HPV16-L1-siE6 carried by attenuated Salmonella has a synergistic effect of immune regulation and RNA interference in cervical cancer treatment.

Cervical cancer prevention in the era of prophylactic vaccines: A preview for gynecologic oncologists

2006 ◽  
Vol 102 (3) ◽  
pp. 552-562 ◽  
Author(s):  
Yvonne Collins ◽  
Mark H. Einstein ◽  
Bobbie S. Gostout ◽  
Thomas J. Herzog ◽  
L. Stuart Massad ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Cancer Prevention ◽  
Cervical Cancer Prevention ◽  
Prophylactic Vaccines

A combined ultrastructural and gene molecular research for the relationship between human uterine cervical carcinoma and human papillomavirus

1990 ◽  
Vol 48 (3) ◽  
pp. 204-205
Author(s):  
Kun Lee ◽  
Jingyi Si ◽  
Ricai Han ◽  
Wei Zhang ◽  
Bingbing Tan ◽  
...  
Keyword(s):  
Cervical Cancer ◽  
Human Papillomavirus ◽  
Intraepithelial Neoplasia ◽  
Hpv Infection ◽  
Dot Blot ◽  
Homologous Sequences ◽  
Normal Cervical Epithelium ◽  
The Relationship ◽  
Chronic Cervicitis

There are more supports for the view that human papillomavirus (HPV) infection might be an etiological factor in the development of cervical cancer when the association of persistent condylomata is considered. Biopsies from 318 cases with squamous cell carcinoma of uterine cervix, 48 with cervical and vulvar condylomata, 14 with cervical intraepithelial neoplasia (CIN), 34 with chronic cervicitis and 24 normal cervical epithelium were collected from 5 geographic regions of China with different cervical cancer mortalities. All specimens were prepared for Dot blot, Southern blot and in situ DNA-DNA hybridizations by using HPV-11, 16, 18 DNA labelled with 32P and 3H as probes to detect viral homologous sequences in samples. Among them, 32 cases with cervical cancer, 27 with condyloma and 10 normal cervical epitheliums were randomly chosen for comparative EM observation. The results showed that: 1), 192 out of 318 (60.4%) cases of cervical cancer were positive for HPV-16 DNA probe (Table I)

Sign in / Sign up

Export Citation Format

Share Document